Ulrich Rothbauer has studied biology at the Ludwig-Maximilians University (LMU) and completed his Diploma in the Lab of Prof. Dr. Svante Pääbo working on the tRNA processing in human mitochondria.
For his PhD he joined the group of Prof. Dr. Walter Neupert revealing the pathomechanism of a mitochondrial disease. In 2003 he started his postdoctoral studies of epigenetic keyfactors in the lab of Prof. Dr. Heinrich Leonhardt at the LMU-Biocenter.
2006 he became an independent group leader starting his work on nanobodies. He established the chromobody technology to study endogenous proteins in living cells and developed novel screening strategies to identify chromobodies for cell cycle analysis, apoptosis studies, proteomics and protein-protein interactions.
2008 he founded the Biotech company ChromoTek, which develops and commercializes new technologies to perform cellular diagnostics and proteomics.
Until 2011 he was managing director of ChromoTek before he became full professor for pharmaceutical biotechnology at the University of Tübingen in 2011.
Governing Activities, Boards
Reviewer for Proteomics, BMC, Nature Structural and Molecular Biology, Analytical Chemistry, Journal of Photonics, Biomacromolecules, FWO